Tracers / [111In]DOTAGA-FAP-2286
[111In]DOTAGA-FAP-2286
Also written as [In-111]In-DOTAGA-FAP-2286
- Radionuclide
- In-111 t½ 4031.6 min
- Modality
- Therapy
- Production route
- —
- Stage
- Reported once
- Syntheses indexed
- 1
What it is
- Compound class
- FAP-targeting peptide radioligand (DOTAGA-conjugated FAP-2286)
- Target / mechanism
- Fibroblast activation protein (FAP) PMID 40236533
- Clinical application
- Cancer (FAP-expressing tumors) diagnosis and therapy PMID 40236533
- Theranostic pair
- —
Regulatory status
- FDA
- —
- EMA (centralised)
- —
- Other approvals
- —
- Brand names
- —
Clinical use
- Typical injected activity
- —
- Uptake time
- —
Reported in the literature. Not a dosing recommendation.
Published syntheses
| Module | Cassette | Purification | Yield % | RCP % | Precursor / supplier | Source |
|---|---|---|---|---|---|---|
| — | — | — | — | — | DOTAGA-FAP-2286 | 40236533 2025 ACS Med Chem Lett |
Need this precursor?We can point you to suppliers for [111In]DOTAGA-FAP-2286, or handle the enquiry for you.
Get in touchNotes
Added at stage 22: promoted from 'Reported once' (single-article, no diagnostic pair at discovery) because a full-text synthesis with extracted data exists in parsed-therapy.xlsx -- PMID(s): 40236533. Target/mechanism, clinical application, indications, approval and precursor fields still need per-agent research and are intentionally left empty. Compound class inferred from precursor name (not stated outright) -- PMID 40236533: 'We designed DOTAGA-FAP-2286 and DOTAGA-FAP-2286-ALB'.